What Vismodegib Treats: Main Uses and Benefits

Vismodegib is a prescription systemic treatment primarily targeting Basal Cell Carcinoma (BCC), the most common type of skin cancer. Its therapeutic application is generally applicable within clinical settings that involve acute or disruptive symptom patterns, and is used for adults whose BCC has metastasized or who have locally advanced disease that has specific anatomical restrictions or is recurrent following local treatments.

Vismodegib is commonly applied in clinical contexts marked by both Locally Advanced Basal Cell Carcinoma (laBCC) and Metastatic Basal Cell Carcinoma (mBCC). It is also relevant in situations involving recurrent or episodic manifestations, and for those with Gorlin Syndrome who develop numerous tumors. It provides supportive relief for conditions where symptoms may intensify temporarily.

“It may assist with maintaining functional stability by easing the overall symptom load.”

---

Quick Fact: Management for Advanced Tumors

Vismodegib is primarily used for managing the symptom domain of uncontrolled tumor proliferation and invasion, which contributes to easing the overall symptom load when the disease involves significant local destruction or systemic spread.

Regulatory References

1. National Cancer Institute overview on Vismodegib

Who Can and Cannot Use Vismodegib?

Vismodegib eligibility is defined by regulatory labels based primarily on age and reproductive status, with use strictly limited to the adult population.

---

Eligibility Scope

Category	Official Regulatory Classification (Summary)
Populations for whom use is allowed (as stated in label)	Adult patients (age ge 18 years)
Populations for whom use is contraindicated	Pregnant females; Breastfeeding females; Patients with known hypersensitivity; Females of reproductive potential not complying with the Pregnancy Prevention Programme.
Age-related eligibility rules	Pediatric use is not indicated and is prohibited due to the risk of premature fusion of the epiphyses (growth plates).
Condition-specific eligibility rules	Hepatic and Renal Impairment: No specific dose adjustment is required for patients with any degree of hepatic or renal impairment.
Pregnancy and lactation eligibility status	Pregnancy: Absolutely Contraindicated (Teratogenic/Embryo-fetal toxicity). Lactation: Contraindicated / Breastfeeding not recommended.
Eligibility-related restrictions	Patients must not donate blood during treatment and for a specified period (e.g., 7 or 24 months) after the final dose. Males must not donate semen during treatment and for a specified period (e.g., 3 months).

---

Eligibility Classifications (High-Level)

Category	Classification Details
Eligibility severity classification	Contraindicated (highest severity for pregnancy/lactation/hypersensitivity). Conditional (for all adults of reproductive potential).
Eligibility-context constraints	Requires enrollment in a Pregnancy Prevention Programme and mandatory use of contraception for both male and female patients of reproductive potential.

Interactions with other medicines and products

The official interaction profile for vismodegib establishes specific co-administration restrictions primarily related to drug metabolism and transporter activity. All interaction information is based strictly on regulatory documents.

A major restriction documented by regulatory authorities is the formal contraindication against the concurrent use of vismodegib with the herbal product St John's wort (Hypericum perforatum).

Vismodegib's efficacy may be compromised by co-administered medicines that are strong inducers of CYP enzymes. Regulatory documents state that combination with agents such as rifampicin, carbamazepine, or phenytoin should be avoided because of the risk for decreased vismodegib plasma concentrations and potential reduced effectiveness.

Conversely, the medication is not expected to have clinically significant pharmacokinetic interactions with several other substance classes. Co-administration with most CYP inhibitors (e.g., fluconazole), P-glycoprotein ( P-gp) inhibitors, and gastric pH elevating agents (e.g., rabeprazole) are formally classified as not being clinically relevant, despite some measured changes in drug exposure.

Vismodegib is also documented as an inhibitor of the BCRP transporter, which may affect the exposure of co-administered BCRP substrates. For patients with severe renal impairment, official labeling advises careful monitoring for adverse reactions.

Direct Blockade of the Smoothened (SMO) Protein

Vismodegib is a selective inhibitor that targets the Smoothened (SMO) protein, a transmembrane component critical to the Hedgehog (Hh) signaling pathway. The drug works by binding directly to the SMO protein, stabilizing it in an inactive conformation and effectively blocking the signal transmission. This action is the primary molecular step that blocks the transmission of a growth-promoting signal driven by this pathway.

Suppression of Proliferation-Driving Gene Activation

The inhibition of SMO prevents the subsequent activation and nuclear translocation of the GLI transcription factors. These factors are transcription factors that regulate genes promoting cell survival and division. By suppressing GLI-mediated gene transcription, Vismodegib interrupts the molecular cascade that fuels cellular activity. This leads to the restraint of cellular proliferation, which contributes to the resulting systemic physiological changes.

Mechanistic Constraints

The action of Vismodegib is primarily focused on the Hh signaling pathway at the level of the SMO protein. This mechanism is functionally constrained by the potential for genetic alterations to occur downstream of SMO, such as mutations in the SUFU protein, which can bypass the drug's block and maintain pathway activity independent of the SMO receptor.

Vismodegib is administered as a 150 mg hard capsule taken orally once daily. The administration protocol is defined by a fixed, continuous regimen overseen by a specialist physician experienced in managing the treated condition. The medicine should be taken at approximately the same time each day, with flexibility regarding meals.

---

Official Administration Guidelines

Feature	Procedural Requirement (150 mg hard capsule)
Route of Administration	Oral.
Dosing Schedule	Fixed dose of 150 mg once daily; dose reduction is not an available option.
Intake Conditions	May be taken with or without food
Handling	The capsule must be swallowed whole with water and must not be opened or crushed to maintain integrity.
Missed Dose Rule	If a dose is missed, do not make up the dose; resume the administration with the next scheduled daily dose.

---

Use Patterns and Population Rules

The treatment plan mandates continuous daily administration until disease progression or until the patient experiences unacceptable tolerability. The treatment protocol allows for a temporary treatment interruption (withholding treatment) ranging from four to eight weeks to manage adverse reactions. The standard 150 mg dose is not subject to adjustment for key populations, including older adults (65 years and over) or patients with renal or hepatic impairment.

---

Connection to the overall use protocol (3 sentences): The official instructions establish a fixed-dose, once-daily, oral regimen as the standardized administration protocol for Vismodegib. This framework governs the continuous use pattern until a defined clinical endpoint is reached. The instructions also define specific procedural constraints, such as the integrity of the capsule and the handling of missed doses, ensuring consistent delivery.

Vismodegib: Recent Clinical Evidence

Vismodegib is a targeted therapy that was initially evaluated in adults with metastatic basal cell carcinoma (mBCC) or locally advanced basal cell carcinoma (laBCC) that had recurred following surgery or for patients who were not candidates for surgery or radiation.

---

Primary Efficacy Findings

The pivotal Phase II trial (ERIVANCE BCC) provided the basis for the drug's use. This single-arm study assessed the Objective Response Rate (ORR), which measures the percentage of patients who experienced a complete or partial tumor shrinkage as determined by independent review.

• For patients with mBCC, the ORR was reported as 30.3% (95% CI: 15.6–48.2).
• For patients with laBCC, the ORR was reported as 42.9% (95% CI: 30.5–56.0). A complete response (no residual BCC found on biopsy) was observed in 20.6% of this group.

The median duration of response in both cohorts was approximately 7.6 months in the initial analysis, suggesting responses were sustained for several months in those who had a positive outcome.

---

Long-Term Follow-up and Safety

Subsequent studies and long-term follow-up of the ERIVANCE trial confirmed the initial findings regarding outcomes and tolerability. The largest study to date, STEVIE, which included over 1,200 patients in a real-world setting, further supported the clinical profile and documented the long-term safety of the therapy.

The most frequently reported Adverse Events (AEs) across the clinical trials (incidence 40%) were:

Adverse Event (All Grades)	Approximate Incidence		Adverse Event (All Grades)	Approximate Incidence
Muscle Spasms	72%		Fatigue	40%
Alopecia (hair loss)	64%		Weight Loss	45%
Dysgeusia (taste change)	55%		Nausea	30%

Discontinuation of treatment due to AEs occurred in approximately 17-29% of patients across the trials. Long-term exposure was generally not associated with an increase in the severity or frequency of new AEs.

Common questions about Vismodegib (FAQ)

---

Q: What is the trade name for Vismodegib?

Vismodegib is the name of the active ingredient. The official trade name for the product is Erivedge^ TM, which is available as an oral hard capsule.

---

Q: What are the rules for blood donation while taking Vismodegib?

Regulatory warnings advise patients not to donate blood or blood products while undergoing treatment with this medicine. Official regulatory documents indicate that this restriction continues for a specific period of at least 7 months following the final dose of the drug.

---

Q: What are the most common side effects of Vismodegib (e.g., muscle cramps)?

The official product information indicates that the most common adverse reactions, occurring in 10% or more of patients in clinical trials, include muscle spasms, hair loss (alopecia), altered sense of taste (dysgeusia), and weight loss. Muscle spasms are contractions or tightening of a muscle.

---

Q: Is there an injection form of Vismodegib, or is it only available as a capsule?

According to the official product information, Vismodegib is supplied only as a capsule designed for oral use. No other forms, such as an injection or a liquid, are listed in the official regulatory prescribing information.

---

Q: Can I open the Vismodegib capsule and mix the contents with food or drink?

Official product information states that the capsule must be swallowed whole and should not be opened, crushed, or chewed. This instruction is necessary to ensure the medicine is delivered correctly according to regulatory specifications.

---

Q: How is Vismodegib eliminated from the body (e.g., urine, stool, liver metabolism)?

Pharmacokinetic data shows that the drug is primarily eliminated from the body through the liver (metabolism). The majority of the drug and its metabolites are recovered in the feces, with a smaller amount recovered in the urine.

How to Store and Dispose of Vismodegib?

Vismodegib hard capsules must be stored according to specific regulatory requirements to maintain product stability and ensure safety.

Official Storage Conditions

• Temperature: Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with permitted short excursions. The medicine must not be frozen.
• Protection: Keep the bottle tightly closed in its original packaging to protect the capsules from moisture and store away from excessive heat and light.
• Handling: The capsules must not be opened, crushed, or chewed to avoid unintended exposure to the active ingredient.

Disposal and Child Safety

It is mandatory to keep Vismodegib out of the sight and reach of children at all times. Any unused, expired, or discontinued capsules must be immediately disposed of according to local guidelines, such as returning them to a pharmacist or physician. The medication must not be thrown into household trash or flushed down the toilet.